2-(4-bromo-2,5-dimethoxyphenyl)ethylamine has been researched along with plx4032 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Czemmel, S; Garbe, C; Groll, N; Ikenberg, K; Krueger, MA; Macek, B; Makino, E; Meier, F; Niessner, H; Pötz, O; Rothbauer, U; Schittek, B; Sinnberg, T; Velic, A | 1 |
1 other study(ies) available for 2-(4-bromo-2,5-dimethoxyphenyl)ethylamine and plx4032
Article | Year |
---|---|
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Resin Cements; STAT3 Transcription Factor; Sulfonamides; Vemurafenib; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |